The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
Authors
Keywords
-
Journal
LEUKEMIA
Volume 34, Issue 7, Pages 1805-1815
Publisher
Springer Science and Business Media LLC
Online
2020-06-09
DOI
10.1038/s41375-020-0891-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China
- (2020) Zunyou Wu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Pathological findings of COVID-19 associated with acute respiratory distress syndrome
- (2020) Zhe Xu et al. Lancet Respiratory Medicine
- Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial
- (2020) Madan Jagasia et al. BLOOD
- Risk Factors of Fatal Outcome in Hospitalized Subjects With Coronavirus Disease 2019 From a Nationwide Analysis in China
- (2020) Ruchong Chen et al. CHEST
- The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China
- (2020) Wen Zhang et al. CLINICAL IMMUNOLOGY
- COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression
- (2020) Dan Zhou et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical and immunological features of severe and moderate coronavirus disease 2019
- (2020) Guang Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- (2020) Marc Feldmann et al. LANCET
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
- (2020) Robert Zeiser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
- (2020) Pavan K. Bhatraju et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cytokine release syndrome in severe COVID-19
- (2020) John B. Moore et al. SCIENCE
- Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base
- (2020) Fabio S Taccone et al. Lancet Respiratory Medicine
- Exploring the Relevance of Senotherapeutics for the Current SARS-CoV-2 Emergency and Similar Future Global Health Threats
- (2020) Marco Malavolta et al. Cells
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease
- (2020) Dennis McGonagle et al. AUTOIMMUNITY REVIEWS
- Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
- (2019) Paul La Rosée et al. BLOOD
- Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis
- (2019) Yanmin Zhao et al. BONE MARROW TRANSPLANTATION
- A journey through infectious risk associated with ruxolitinib
- (2019) Emanuela Sant’Antonio et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis
- (2019) Jingshi Wang et al. HAEMATOLOGICA
- Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial
- (2019) Asra Ahmed et al. Lancet Haematology
- Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society
- (2018) Stephan Ehl et al. Journal of Allergy and Clinical Immunology-In Practice
- Inflammation and myeloproliferative neoplasms
- (2017) Federico Lussana et al. JOURNAL OF AUTOIMMUNITY
- Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function
- (2015) F Perner et al. LEUKEMIA
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
- (2014) Yan Beauverd et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now